Literature DB >> 33447844

Sleep apnoea has a dose-dependent effect on atrial remodelling in paroxysmal but not persistent atrial fibrillation: a high-density mapping study.

Chrishan Joseph Nalliah1,2, Geoffrey R Wong1,2, Geoffrey Lee1,2, Aleksandr Voskoboinik3,4, Kirk Kee2,3, Jeremy Goldin2,3, Troy Watts1, Dominik Linz5, Daniel Wirth1, Ramanathan Parameswaran1,2, Hariharan Sugumar2,4, Sandeep Prabhu2,4, Alex McLellan1,2, Han Ling2,4, Stephen Joseph1,2, Joseph B Morton1,2, Peter Kistler2,4, Prashanthan Sanders5, Jonathan M Kalman1,2.   

Abstract

AIMS: Obstructive sleep apnoea (OSA) associates with atrial fibrillation (AF), but the relationship of OSA severity and AF phenotype with the atrial substrate remains poorly defined. We sought to define the atrial substrate across the spectrum of OSA severity utilizing high-density mapping. METHODS AND
RESULTS: Sixty-six consecutive patients (male 71%, age 61 ± 9) having AF ablation (paroxysmal AF 36, persistent AF 30) were recruited. All patents underwent formal overnight polysomnography and high-density left atrial (LA) mapping (mean 2351 ± 1244 points) in paced rhythm. Apnoea-hypopnoea index (AHI) (mean 21 ± 18) associated with lower voltage (-0.34, P = 0.005), increased complex points (r = 0.43, P < 0.001), more low-voltage areas (r = 0.42, P < 0.001), and greater voltage heterogeneity (r = 0.39, P = 0.001), and persisted after multivariable adjustment. Atrial conduction heterogeneity (r = 0.24, P = 0.025) but not conduction velocity (r = -0.09, P = 0.50) associated with AHI. Patchy regions of low voltage that co-localized with slowed conduction defined the atrial substrate in paroxysmal AF, while a diffuse atrial substrate predominated in persistent AF. The association of AHI with remodelling was most apparent among paroxysmal AF [LA voltage: paroxysmal AF -0.015 (-0.025, -0.005), P = 0.004 vs. persistent AF -0.006 (-0.017, 0.005), P = 0.30]. Furthermore, in paroxysmal AF an AHI ≥ 30 defined a threshold at which atrial remodelling became most evident (nil-mild vs. moderate vs. severe: 1.92 ± 0.42 mV vs. 1.84 ± 0.28 mV vs. 1.34 ± 0.41 mV, P = 0.006). In contrast, significant remodelling was observed across all OSA categories in persistent AF (1.67 ± 0.55 mV vs. 1.50 ± 0.66 mV vs. 1.55 ± 0.67 mV, P = 0.82).
CONCLUSION: High-density mapping observed that OSA associates with marked atrial remodelling, predominantly among paroxysmal AF cohorts with severe OSA. This may facilitate the identification of AF patients that stand to derive the greatest benefit from OSA management. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Atrial remodelling; Atrial substrate; High-density mapping; Obstructive sleep apnoea

Year:  2021        PMID: 33447844     DOI: 10.1093/europace/euaa275

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

1.  OpenEP: A Cross-Platform Electroanatomic Mapping Data Format and Analysis Platform for Electrophysiology Research.

Authors:  Steven E Williams; Caroline H Roney; Adam Connolly; Iain Sim; John Whitaker; Daniel O'Hare; Irum Kotadia; Louisa O'Neill; Cesare Corrado; Martin Bishop; Steven A Niederer; Matt Wright; Mark O'Neill; Nick W F Linton
Journal:  Front Physiol       Date:  2021-02-26       Impact factor: 4.566

2.  Pharmacological inhibition of acetylcholine-regulated potassium current (I K,ACh) prevents atrial arrhythmogenic changes in a rat model of repetitive obstructive respiratory events.

Authors:  Benedikt Linz; Anne Hauge Thostrup; Arnela Saljic; Karlijn Rombouts; Julie Norup Hertel; Mathias Hohl; James Milnes; Jacob Tfelt-Hansen; Dominik Linz; Thomas Jespersen
Journal:  Heart Rhythm O2       Date:  2021-11-19

3.  Risk of New-Onset Atrial Fibrillation Post-cavotricuspid Isthmus Ablation in Typical Atrial Flutter Without History of Atrial Fibrillation.

Authors:  Jia-Hui Li; Hai-Yang Xie; Yan-Qiao Chen; Zhong-Jing Cao; Qing-Hui Tang; Xiao-Gang Guo; Qi Sun; Jian Ma
Journal:  Front Physiol       Date:  2021-11-30       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.